NJ S2875

Exempts drug manufacturers and wholesale drug distributors from pharmacist licensing requirements when distributing dialysate drugs and devices for home dialysis to patients with end-stage renal disease

Requires dialysate drugs and devices to be FDA-approved, held by properly registered entities, and delivered in original sealed packaging from the manufacturing facility

Limits delivery to direct recipients including patients with end-stage renal disease (or their designees) and health care providers or institutions administering dialysis therapy

Mandates manufacturers contract with a board-registered consultant pharmacist to conduct weekly quality assurance assessments of home dialysis drug storage and distribution

Takes effect on the first day of the third month following enactment